Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Continuing bevacizumab with second-line chemotherapy for colorectal cancer

2012 ASCO Annual Meeting

Published: 3 Jun 2012

Views: 5148

Rating:

Save

Dr Dirk Arnold - University Cancer Center Hamburg, Germany

At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr Dirk Arnold presents results from a phase III clinical trial showing that combination treatment with bevacizumab and standard chemotherapy in the second line setting extends overall survival in patients with advanced colorectal cancer after receiving bevacizumab combination treatment.

ecancerNews Coverage

Related Videos

Zolbetuximab plus nivolumab and chemotherapy shows promising responses in CLDN18.2-positive metastatic gastric cancer

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan

Zolbetuximab plus nivolumab and chemotherapy shows promising responses in CLDN18.2-positive metastatic gastric cancer ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )

Zanidatamab improves PFS and OS in first-line HER2-positive metastatic gastric cancer

Dr Elena Elimova - The Princess Margaret Hospital, Toronto, Canada

Zanidatamab improves PFS and OS in first-line HER2-positive metastatic gastric cancer ( Dr Elena Elimova - The Princess Margaret Hospital, Toronto, Canada )

Optimal management of gastric cancers

Dr Prasanth Penumadu - Institution of Cancer Care & Advanced Research , Tirupati, India.

Optimal management of gastric cancers ( Dr Prasanth Penumadu - Institution of Cancer Care & Advanced Research , Tirupati, India. )

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini

ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )

Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients

Dr Prashant Mehta - Amrita Hospital, Karala, India

Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients ( Dr Prashant Mehta - Amrita Hospital, Karala, India )

Advancements in head and neck cancer treatment in India

Dr Amol Akhade - Tata Memorial Hospital, Mumbai, India

Advancements in head and neck cancer treatment in India ( Dr Amol Akhade - Tata Memorial Hospital, Mumbai, India )

Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advanced GEJ cancer

Dr Giovanni Randon - The National Cancer Institute of Milan, Milano, Italy

Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advanced GEJ cancer ( Dr Giovanni Randon - The National Cancer Institute of Milan, Milano, Italy )

Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine carcinomas shows efficacious results

Dr Lorraine Chantrill - University of Sydney, Sydney, Australia

Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine carcinomas shows efficacious results ( Dr Lorraine Chantrill - University of Sydney, Sydney, Australia )

Trifluridine/tipiracil and bevacizumab combination gives a prolonged PFS compared to trifluridine/tipiracil monotherapy in mCRC

Prof Hironaga Satake - Kochi Medical School, Kochi, Japan

Trifluridine/tipiracil and bevacizumab combination gives a prolonged PFS compared to trifluridine/tipiracil monotherapy in mCRC ( Prof Hironaga Satake - Kochi Medical School, Kochi, Japan )

More from ecancer